

**CURRICULUM VITAE**

**INFORMAZIONI PERSONALI**

Nome	<b>Sarchi Martina</b>
Qualifica	<b>MD, PhD</b>
Amministrazione	<b>Dipartimento di Medicina Molecolare</b>
Incarico attuale	<b>Ricercatore a tempo determinato, RTD-A</b>
E-mail istituzionale	<b>martina.sarchi@unipv.it</b>

**TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE**

Titolo di studio	<b>2019 – 2023</b>	Dottorato di Ricerca in Scienze Biomediche Università di Pavia, Italia
	<b>2012-2019</b>	Master in Scienze Biomediche IUSS Pavia, Italia
	<b>2012-2018</b>	Laurea in Medicina e Chirurgia Università di Pavia, Italia
Altri titoli di studio e professionali	<b>2019</b>	Abilitazione all'esercizio professionale
Esperienze professionali	<b>04/2024 –</b>	Ricercatore a tempo determinato, RTD-A Settore disciplinare MED/04 Università di Pavia, Italia
	<b>04/2023 – 03/2024</b>	Assegnista di ricerca – AIRC Post-Doc Fellow Università di Pavia, Italia
	<b>10/2019 – 04/2023</b>	Dottorato di ricerca 10/2019 – 04/2023 Università di Pavia, Italia 03/2020 – 06/2023 University of Washington, Seattle, WA
	<b>02/2019 – 09/2019</b>	Borsista di ricerca Università di Pavia, Italia
	<b>08/2018 – 01/2019</b>	Research Fellow Harvard Medical School, Boston, MA
	<b>10/2016 – 06/2018</b>	Internato di tesi in Medicina e Chirurgia Università di Pavia, Italia
	<b>07/2017 – 09/2017</b>	Summer Intern Harvard Medical School, Boston, MA
	<b>06/2016 – 08/2016</b>	Summer Intern Harvard Medical School, Boston, MA
	<b>09/2015 – 05/2016</b>	Studente volontario IRCCS Policlinico San Matteo, Pavia, Italy
	<b>08/2015</b>	Summer Intern MRC Cancer Unit, Cambridge, UK
Capacità linguistiche	<b>Inglese</b>	
Capacità nell'uso delle tecnologie	<b>Ottime</b>	

Pubblicazioni	<ol style="list-style-type: none"> <li>1. Sarchi M, Clough CA*, Crosse EI*, Kim J*, Baquero Galvis LD, Aydinyan N, Wellington R, Yang F, Galli A, Creamer JP, Stewart S, Bradley RK, Malcovati L, Doulatov S. Mis-splicing of mitotic regulators sensitizes SF3B1-mutated human HSCs to CHK1 inhibition. <i>Blood Cancer Discov.</i> 2024.</li> <li>2. Benbarche S*, Pineda JMB*, Galvis LB*, Biswas J, Liu B, Wang E, Zhang Q, Hogg SJ, Lyttle K, Dahi A, Lewis AM, Sarchi M, Rahman J, Fox N, Ai Y, Mehta S, Garippa R, Ortiz-Pacheco J, Li Z, Monetti M, Stanley RF, Doulatov S, Bradley RK, Abdel-Wahab O. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. <i>Mol Cell.</i> 2024 May 16;84(10):1886-1903.e10.</li> <li>3. Liu ZS*, Sinha S*, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphappaiboon W, Leibson C, McMahon MC, Rai S, Swisher EM, Sachs Z, Chatla S, Stirewalt DL, Deeg HJ, Skorski T, Papapetrou EP, Walter MJ, Graubert TA, Doulatov S, Lee SC, Nguyen HD. R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts. <i>Cancer Res.</i> 2024 Feb 15;84(4):577-597.</li> <li>4. Molteni E*, Bono E*, Galli A, Elena C, Ferrari J, Fiorelli N, Pozzi S, Ferretti VV, Sarchi M, Rizzo E, Camilotto V, Boveri E, Cazzola M, Malcovati L. Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity. <i>Blood.</i> 2023 Aug 17;142(7):643-657.</li> <li>5. Clough CA, Pangallo J*, Sarchi M*, Ilagan JO*, North K, Bergantinos R, Stolla MC, Naru J, Nugent P, Kim E, Stirewalt DL, Subramaniam AR, Abdel-Wahab O, Abkowitz JL, Bradley RK, Doulatov S. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. <i>Blood.</i> 2022 Mar 31;139(13):2038-2049.</li> <li>6. Galli A, Todisco G, Catamo E, Sala C, Elena C, Pozzi S, Bono E, Ferretti VV, Rizzo E, Molteni E, Zibellini S, Sarchi M, Boveri E, Ferrari J, Fiorelli N, Camaschella C, Gasparini P, Toniolo D, Cazzola M, Malcovati L. Relationship between clone metrics and clinical outcome in clonal cytopenia. <i>Blood.</i> 2021 Sep 16;138(11):965-976.</li> <li>7. Todisco G, Creignou M, Galli A, Guglielmelli P, Rumi E, Roncador M, Rizzo E, Nannya Y, Pietra D, Elena C, Bono E, Molteni E, Rosti V, Catricalá S, Sarchi M, Dimitriou M, Ungerstedt J, Vannucchi AM, Hellström-Lindberg E, Ogawa S, Cazzola M, Malcovati L. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasms. <i>Leukemia.</i> 2021 Aug;35(8):2371-2381.</li> </ol>
Presentazioni a seminari e conferenze	<ol style="list-style-type: none"> <li>1. Sarchi M, Clough CA, Crosse EI, Kim J, Baquero Galvis LD, Aydinyan N, Wellington R, Galli A, Creamer JP, Stewart S, Pozzi S, Molteni E, Elena C, Bradley RK, Malcovati L, Doulatov S. Mitotic dysregulation sensitizes malignant stem cells to CHK1 inhibition in SF3B1-myeloid neoplasms. 65th ASH Annual Meeting. <i>Blood</i> (2023). (<i>Oral presentation – San Diego, USA; 2023</i>).</li> <li>2. Sarchi M., Malcovati L., Doulatov S. SF3B1-mutant myelodysplastic syndromes: clonal trajectories and therapeutic</li> </ol>

	<p>targeting. 2023 Hematology Faculty/Fellows Retreat. (<i>Oral presentation - Seattle, USA; 2023</i>).</p> <p>3. Sarchi M., Clough C.A., Crosse E.I., Kim, J., Baquero Galvis L. D., Galli A., Creamer J.P., Stewart S., Pozzi S, Molteni E., Elena C., Bradley R.K., Malcovati L., and Doulatov S. CHK1 inhibition targets malignant stem cells in <i>SF3B1</i>-mutant myeloid neoplasms. 4<sup>th</sup> Workshop on splicing factor mutations and RNA biology in cancer. (<i>Poster presentation – New York, USA; 2023</i>).</p> <p>4. Sarchi M., Malcovati L., Doulatov S. <i>SF3B1</i>-mutant myelodysplastic syndromes: clonal trajectories and therapeutic targeting. Invited speaker at Department of Molecular Medicine Seminars, University of Pavia. (<i>Oral presentation - Pavia, Italy; 2023</i>).</p> <p>5. Sarchi M., Clough C.A., Galli A., Todisco G., Creamer J.P., Malcovati L. and Doulatov S. Clonal trajectories and therapeutic targeting of high-risk <i>SF3B1</i>-mutant myelodysplastic syndromes. 64th ASH Annual Meeting. <i>Blood</i> (2022). (<i>Oral presentation - New Orleans, USA 2022</i>).</p> <p>6. Sarchi M., Clough C.A., Galli A., Todisco G., Creamer J.P., Malcovati L. and Doulatov S. Clonal trajectories and therapeutic targeting of high-risk <i>SF3B1</i>-mutant myelodysplastic syndromes. Fred Hutchinson SCGT &amp; University of Washington Heme Meeting. (<i>Oral presentation - Seattle, USA; 2022</i>).</p> <p>7. Sarchi M., Malcovati L., and Doulatov S. Clonal trajectories of high-risk <i>SF3B1</i>-mutant myelodysplastic syndromes. 2022 ISCRM Symposium “Human pluripotent stem cell-derived hematopoiesis”. (<i>Oral presentation - Seattle, USA; 2022</i>).</p> <p>8. Sarchi M., Clough C.A., Galli A., Todisco G., Creamer J.P., Malcovati L. and Doulatov S. Clonal trajectories and therapeutic targeting of high-risk <i>SF3B1</i>-mutant myelodysplastic syndromes. 2022 Hematology Faculty/Fellows Retreat. (<i>Oral presentation - Seattle, USA; 2022</i>).</p> <p>9. Sarchi M., Galli A., Clough C.A., Todisco G., Creamer J.P., Malcovati L., and Doulatov S. Modeling clonal progression in <i>SF3B1</i>-mutant myelodysplastic syndrome. 63rd ASH Annual Meeting. <i>Blood</i> (2021) 138 (Supplement 1): 149. (<i>Oral presentation - Atlanta, USA; 2021</i>).</p> <p>10. Sarchi M., Galli A., Clough C.A., Todisco G., Creamer J.P., Malcovati L., and Doulatov S. Modeling clonal progression in <i>SF3B1</i>-mutant myelodysplastic syndrome. Fred Hutchinson SCGT &amp; University of Washington Heme Meeting (<i>Oral presentation - virtual conference; 2021</i>).</p> <p>11. Sarchi M., Malcovati L. and Doulatov S. Modeling clonal progression in <i>SF3B1</i>-mutant myelodysplastic syndrome. 2021 Hematology Faculty/Fellows Retreat. (<i>Oral presentation - Seattle, USA; 2021</i>).</p> <p>12. Sarchi M., Shulga Y., Pandolfi P.P. The role of MARCKS in prostate cancer, SWAP Academic Talks, St. John's College (<i>Oral presentation – Cambridge, UK; 2017</i>).</p> <p>13. Sarchi M., Shulga Y., Pandolfi P.P. The role of MARCKS in prostate cancer, Armenian-Harvard Summer Fellowship Research Day (<i>Oral presentation - Boston, USA; 2016</i>).</p>
--	--

Premi e riconoscimenti	<ol style="list-style-type: none"> <li>1. ASH Abstract Achievement Award (2023)</li> <li>2. AIRC Post-Doc Fellowship (2023)</li> <li>3. ASH Abstract Achievement Award (2022)</li> <li>4. ASH Abstract Achievement Award (2021)</li> <li>5. Laureato dell'anno in Medicina e Chirurgia (2019)</li> <li>6. Premio Giuseppe Teresio Bonizzoni (Fondazione Ferrata Storti) (2019)</li> <li>7. Alunna del Collegio Ghislieri (2012-2018)</li> <li>8. Premio Augusto Trombini (Collegio Ghislieri) (2018)</li> <li>9. Armenise-Harvard Summer Fellowship (2016)</li> <li>10. Borsa di studio al St John's College, Cambridge (UK) (2015)</li> </ol>
------------------------	--

Il sottoscritto, consapevole che – ai sensi dell’art. 76 del D.P.R. 445/2000 – le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni rispondono a verità.

Il sottoscritto dichiara di aver ricevuto l’informativa sul trattamento dei dati personali, pubblicata al seguente link: <https://privacy.unipv.it>.

Il sottoscritto è consapevole che il presente documento potrebbe essere oggetto di pubblicazione per finalità di trasparenza sul sito web dell’Università degli Studi di Pavia.

Luogo e data  
Pavia, 9 giugno 2024